AVBCC 2021 Summit

With better insights into the biology of cancer and other diseases, genetic medicine is entering “a whole new ballgame,” said Scott Gottlieb, MD, Former FDA Commissioner, during the keynote session at the 11th Annual Summit of the Association for Value-Based Cancer Care in 2021.
Read Article

Community-based providers remain at the core of the oncology care delivery system. A panel moderated by Barbara McAneny, MD, Chief Executive Officer, New Mexico Oncology Hematology Consultants, Albuquerque, at the 11th Annual Summit of the Association for Value-Based Cancer Care in 2021 explored the road ahead for community practices in terms of balancing value and delivering optimal access to care for patients.
Read Article

Many innovative therapies in oncology have made it to market recently, with a wealth of agents that are currently on the verge of FDA approval.
Read Article

The success of oncology support services developed by pharmaceutical manufacturers depends on tailoring programs that meet the needs of their specific patient populations, said panelists at a roundtable discussion on patient centricity and connectivity in oncology support and HUB services.
Read Article

At the 11th Annual Summit of the Association for Value-Based Cancer Care (AVBCC) in 2021, health plans and employers discussed the utility of value-based contracting for managing oncology care costs while maintaining focus on outcomes of value for patients.
Read Article

Enhanced flexibility in delivery, increased investment in digital capability, and quick adaptation to events were some of the positive impacts of the COVID-19 pandemic on cancer care.
Read Article

Oncologic drug pricing is being transformed with greater value in mind. At the 11th Annual Summit of the Association for Value-Based Cancer Care in 2021, a panel led by moderator William McGivney, PhD, Managing Principal, McGivney Global Advisors, Wayne, PA, discussed innovation in drug pricing, how the current rebate system supports higher drug costs, balancing new interventions with profits, and the implications of drug price negotiations being considered in Congress.
Read Article

The use of telehealth in the fee-for-service program surged by more than 4000% during the first 6 months of the COVID-19 pandemic.
Read Article

Reducing disparities in cancer care, including those affecting research and treatment, requires a better understanding of the history of racism, noted experts during a panel discussion at the 11th Annual Summit of the Association for Value-Based Cancer Care in 2021. The panel, which was moderated by Sybil Green, JD, RPh, MHA, Diversity and Inclusion Officer, American Society of Clinical Oncology, examined barriers to equitable care and potential solutions to remove these barriers.
Read Article

Currently, 31 biosimilar products have been approved by the FDA, 20 of which have been launched in the United States.
Read Article

Page 1 of 2